Objective: To study changes of peripheral blood lymphocyte calcineurin/ nuclear factor of activated T cells (CaN/NFAT) signaling pathway and calcium activated potassium channel (KCa3.1) expression in Kazak hypertensive patients with high high sensitive C reactive protein (hsCRP) level from Xinjiang, and explore the mechanism of lymphocyte potassium channel involving in inflammation of hypertension.Methods: Kazak hypertensive patients from Xinjiang, who were first diagnosed in our heart center without antihypertensive therapy from Feb 2014 to Nov 2014, were selected.According to detected hsCRP level, a total of 50 hsCRP≥3mg/L patients were enrolled as high hsCRP group, and 50 hsCRP<3mg/L patients were enrolled as normal hsCRP group.Gene and protein expression levels of KCa3.1 and tumor necrosis factor (TNF)-α, and activities of lymphocyte CaN and NFAT were measured and compared between two groups.Results: Compared with normal hsCRP group, there were significant rise in expression levels of lymphocyte KCa3.1 mRNA [(0.86±0.16) vs.(2.48±0.22)], TNF-α mRNA [(1.02±0.15) vs.(2.90±0.13)], KCa3.1 protein [(1.00±0.02) vs.(2.46±0.04)] and TNF-α protein [(1.01±0.02) vs.(2.04±0.06)], and activities of CaN [(1.04±0.15) vs.(2.83±0.08)] and NFAT [(0.96±0.06) vs.(2.65±0.07)] in high hsCRP group, P<0.01 all.Conclusion: In Kazak hypertensive patients with inflammatory reaction from Xinjiang, KCa3.1 and CaN-NFAT signaling pathway expression rises, suggesting that lymphocyte KCa3.1 may be involved in occurrence and development of hypertension via CaN/NFAT signaling pathway.

[Abstract] Objective: To systematically evaluate the efficacy and safety of ramcircumab in the treatment of advanced non-small cell lung cancer (NSCLC) by a Meta-analysis. Methods: The randomized controlled clinical trials of ramcircumab in the treatment of advanced non-small cell lung cancer were retrieved from Cochrane Library (2017, Issue 8), Web of Science, Pubmed, EMbase, Wanfang Database, CNKI, CBM, Chinese Science and TechnologyAcademic Journal andASCO, ESMO main conference database, with the enddate of September 1, 2017. Two independent reviewers selected the literatures, extracted the data, and assessed the quality of the included studies. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse reactions in NSCLC patients of ramcircumab group and control group were analyzed by RevMan5.3 software. Results: Three RCTs were finally included in this meta-analysis. A total of 1 545 NSCLC patients were enrolled, including 777 in ramcircumab group and 768 in control group. The PFS and OS of NSCLC patients in the ramcircumab group were all better than those of the control group (HR=0.77,95%CI[0.69-0.85], P<0.01; HR=0.88, 95%CI[0.78-0.99], P<0.05). However, there was no statistically significant difference in the ORR between the ramcircumab group and the control group (RR=1.33, 95%CI[0.68-2.61], P>0.05). Compared with docetaxel single-agent second-line treatment, Ramcircumab combined with docetaxel can prolong PFS and OS of advanced NSCLC patients (HR=0.77, 95%CI[0.69-0.86], P< 0.01; HR=0.86, 95%CI [0.76-0.98], P<0.05). The most serious adverse reaction in the ramcircumab group was hypertension (RR=3.33, 95%CI[1.83-6.05], P<0.01); whereas the incidences of nausea, vomiting, diarrhea, loss of appetite, fatigue, proteinuria, neutropenia, leukopenia, thrombocytopenia, and bleeding etc. showed no significant differences between the two groups (all P>0.05). Conclusion: Ramcircumab can prolong PFS and OS of patients with advanced NSCLC. The main adverse reaction is hypertension.

[摘 要] 目的：系统评价单药程序性死亡受体1（PD-1）抑制剂对比化疗二线治疗晚期食管鳞状细胞癌（ESCC）患者的疗效及安全性，以期为临床决策提供最佳循证医学证据。方法：计算机检索The Cochrane Library、Web of Science、PubMed、EMbase、CNKI和万方等数据库，同时检索J Clin Oncol、N England Oncol、Lancet Oncol等杂志以及ASCO、EMSO会议摘要中有关单药PD-1抑制剂对比传统化疗二线治疗晚期ESCC患者的临床随机对照试验（RCT），筛选文献，提取资料，采用RevMan5.3进行Meta分析。结果：共纳入5项RCT研究（1 732例患者）。与化疗组比，单药PD-1抑制剂二线治疗晚期ESCC可显著延长患者的总生存期（OS）（HR＝0.75，95% CI：0.67~0.83，P<0.000 01）。以PD-L1不同表达程度进行亚组分析，在延长OS方面，TPS<1%时，单药PD-1抑制剂二线治疗晚期ESCC无明显优势；而TPS≥1%、TPS<5%、TPS≥5%、TPS<10%、TPS≥10%时，单药PD-1抑制剂二线治疗均可显著延长晚期ESCC患者的OS，且PD-L1表达程度越高，疗效获益更显著。然而，与化疗组比，单药PD-1抑制剂在延长晚期ESCC患者的无进展生存期（PFS）（HR＝0.93，95% CI：0.79~1.10，P=0.41）及提高客观有效率（ORR）（RR＝1.62，95% CI：0.95~2.74，P=0.07）等方面，差异均无统计学意义。但单药PD-1抑制剂组3~5级不良反应发生率低（RR＝0.37，95% CI：0.28~0.50，P<0.000 01）。结论：单药PD-1抑制剂二线治疗晚期ESCC患者可显著延长患者的OS；PD-L1高表达者PD-1抑制剂可作为二线治疗的优先选择，且具有良好的安全性。 , , , , , ()